We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips
Read MoreHide Full Article
Amedisys, Inc. (AMED - Free Report) reported earnings per share (EPS) of $1 in the second quarter of 2018, up 61.2% from the year-ago adjusted EPS of 62 cents. The bottom line also remained well ahead of the Zacks Consensus Estimate of 78 cents.
Second-quarter net service revenues grossed $411.6 million, up 9.8% year over year. Moreover, the top line also beat the Zacks Consensus Estimate of $404 million.
Quarter in Detail
Within the company's Home Health division, net service revenues totaled $291.5 million in the second quarter, reflecting a 7.8% improvement year over year. Medicare revenues of $206.3 million rose 4% year over year while non-Medicare revenues improved 18.3% year over year to $72 million.
Within the Hospice division, net service revenues grossed $101.4 million (up 12.3% year over year) including Medicare revenues of $96.9 million (up 12.9%) and non-Medicare revenues of $4.5 million (flat year over year).
Recently, the company integrated two additional operating segments within its business, namely Personal Care and Corporate. At Personal Care, net service revenues totaled $18.7 million, representing a 30.8% surge from the year-ago number. Meanwhile, the Corporate segment did not register any revenues till the end of the second quarter.
The company’s gross margin contracted 11 basis points (bps) to 41.1% in the quarter under review despite a 9.5% gain in gross profit. Expense on salaries and benefits rose 3% to $77.2 million. Other expenses inched up 1.2% to $42.1 million. Adjusted operating income of $49.7 million in the reported quarter reflects a 31.4% rise from the year-ago tally. Adjusted operating margin expanded 199 bps to 12.1% from the year-ago figure.
Amedisys exited the second quarter of 2018 with cash and cash equivalents of $25.9 million compared with $120 million at the end of the first quarter. The company's long-term obligations (excluding current portion) were $123.9 million at the end of the second quarter compared with $75.8 million at the end of the first quarter. Net cash provided by operating activities in the first half of 2018 was $50.7 million compared with $36.2 million in the year-ago period.
Our Take
Amedisys ended the second quarter on a promising note with both earnings and revenues exceeding the respective Zacks Consensus Estimate. At the Home Health and Hospice divisions, the company witnessed encouraging growth in Medicare and non-Medicare revenues. Amedisys is currently exploring opportunities in these segments. We are also impressed by the company’s solid performance in the recently launched Personal Care segment. A favorable demographic trend and strategic acquisitions also bode well for the company.
However, escalating operating expenses and a declining gross margin continue to raise concerns. Also, an intense competitive landscape and regulatory concerns persistently pose challenges to the home health and hospice industry.
Zacks Rank & Key Picks
Amedisys sports a Zacks Rank #1 (Strong Buy). A few other top-ranked stocks in the broader medical sector having reported solid results this earnings season so far are Intuitive Surgical (ISRG - Free Report) , Chemed Corporation (CHE - Free Report) and Align Technology, Inc. (ALGN - Free Report) . While Intuitive Surgical sports a Zacks Rank of 1, Chemed and Align Technology carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical reported second-quarter 2018 adjusted EPS of $2.76, which beat the Zacks Consensus Estimate of $2.48. Revenues totaled $909.3 million, also surpassing the consensus estimate of $870 million.
Chemed reported second-quarter 2018 adjusted EPS of $2.81, which trumped the Zacks Consensus Estimate of $2.68. Revenues of $441.8 million edged past the Zacks Consensus Estimate of $432.3 million.
Align Technology posted second-quarter 2018 adjusted EPS of $1.30, steering past the Zacks Consensus Estimate of $1.09. Revenues came in at $490.3 million, beating the consensus estimate of $462.9 million.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips
Amedisys, Inc. (AMED - Free Report) reported earnings per share (EPS) of $1 in the second quarter of 2018, up 61.2% from the year-ago adjusted EPS of 62 cents. The bottom line also remained well ahead of the Zacks Consensus Estimate of 78 cents.
Second-quarter net service revenues grossed $411.6 million, up 9.8% year over year. Moreover, the top line also beat the Zacks Consensus Estimate of $404 million.
Quarter in Detail
Within the company's Home Health division, net service revenues totaled $291.5 million in the second quarter, reflecting a 7.8% improvement year over year. Medicare revenues of $206.3 million rose 4% year over year while non-Medicare revenues improved 18.3% year over year to $72 million.
Within the Hospice division, net service revenues grossed $101.4 million (up 12.3% year over year) including Medicare revenues of $96.9 million (up 12.9%) and non-Medicare revenues of $4.5 million (flat year over year).
Amedisys, Inc. Price, Consensus and EPS Surprise
Amedisys, Inc. Price, Consensus and EPS Surprise | Amedisys, Inc. Quote
Recently, the company integrated two additional operating segments within its business, namely Personal Care and Corporate. At Personal Care, net service revenues totaled $18.7 million, representing a 30.8% surge from the year-ago number. Meanwhile, the Corporate segment did not register any revenues till the end of the second quarter.
The company’s gross margin contracted 11 basis points (bps) to 41.1% in the quarter under review despite a 9.5% gain in gross profit. Expense on salaries and benefits rose 3% to $77.2 million. Other expenses inched up 1.2% to $42.1 million. Adjusted operating income of $49.7 million in the reported quarter reflects a 31.4% rise from the year-ago tally. Adjusted operating margin expanded 199 bps to 12.1% from the year-ago figure.
Amedisys exited the second quarter of 2018 with cash and cash equivalents of $25.9 million compared with $120 million at the end of the first quarter. The company's long-term obligations (excluding current portion) were $123.9 million at the end of the second quarter compared with $75.8 million at the end of the first quarter. Net cash provided by operating activities in the first half of 2018 was $50.7 million compared with $36.2 million in the year-ago period.
Our Take
Amedisys ended the second quarter on a promising note with both earnings and revenues exceeding the respective Zacks Consensus Estimate. At the Home Health and Hospice divisions, the company witnessed encouraging growth in Medicare and non-Medicare revenues. Amedisys is currently exploring opportunities in these segments. We are also impressed by the company’s solid performance in the recently launched Personal Care segment. A favorable demographic trend and strategic acquisitions also bode well for the company.
However, escalating operating expenses and a declining gross margin continue to raise concerns. Also, an intense competitive landscape and regulatory concerns persistently pose challenges to the home health and hospice industry.
Zacks Rank & Key Picks
Amedisys sports a Zacks Rank #1 (Strong Buy). A few other top-ranked stocks in the broader medical sector having reported solid results this earnings season so far are Intuitive Surgical (ISRG - Free Report) , Chemed Corporation (CHE - Free Report) and Align Technology, Inc. (ALGN - Free Report) . While Intuitive Surgical sports a Zacks Rank of 1, Chemed and Align Technology carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical reported second-quarter 2018 adjusted EPS of $2.76, which beat the Zacks Consensus Estimate of $2.48. Revenues totaled $909.3 million, also surpassing the consensus estimate of $870 million.
Chemed reported second-quarter 2018 adjusted EPS of $2.81, which trumped the Zacks Consensus Estimate of $2.68. Revenues of $441.8 million edged past the Zacks Consensus Estimate of $432.3 million.
Align Technology posted second-quarter 2018 adjusted EPS of $1.30, steering past the Zacks Consensus Estimate of $1.09. Revenues came in at $490.3 million, beating the consensus estimate of $462.9 million.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>